Evidence-Based Gastroenterology and Hepatology (Evidence-Based Medicine)

0.0

The only evidence-based  resource combining  gastroenterology and hepatology, this major textbook critically appraises the evidence for diagnosis, screening, and treatment of gastrointestinal and hepatic diseases, and provides clear recommendations for management.A unique feature is the grading of both the evidence (randomized controlled trials, systematic reviews, or lower quality trials) and the treatment recommendations. This structure provides the reader with valuable guidance on implementation.The third edition has been fully revised, providing the latest reviews of the evidence. It is also enhanced with new topics that have significant evidence for treatment, including;Esinophilic esophagitisAcute dysenteriesPrevention and treatment of  travellers’ diarrhoeaFrequency of adverse drug effects on bowel functionManagement of hepatitis B Management of Hepatitis CVascular disorder of the liver Non invasive diagnosis of liver fibrosisDrug induced liver disease

0.0

John McDonald, Professor of Gastroenterology at the University of Ontario, London Ontario, Coordinating Editor in the Cochrane Collaboration Steering Committee on methodology, and Past President of the Canadian College of GastroenterologyProfessor Andrew Burroughs MBChB Hons FRCPConsultant Physician and Hepatologist, Royal Free Hospital, London, has an international reputation as a clinical and academic Hepatologist and has published widely in all areas of liver disease. He is a full time clinician and has been awarded a personal chair, as Professor of Hepatology in the University of London.Brian Feagan is Professor of Medicine and Epidemiology and Biostatistics at the University of Western Ontario. He holds cross-appointments in the Divisions of Internal Medicine, Clinical Pharmacology and Gastroenterology. He is a specialist in Internal Medicine with training in Clinical Epidemiology and Gastroenterology who has been the lead investigator in the design and implementation of randomized controlled trials since 1986. In addition to being an internationally recognized expert in the therapy of Inflammatory Bowel Disease, Dr. Feagan has conducted trials on behalf of Industry and peer-reviewed agencies in a wide range of disease states. Dr. Feagan is interested in the evaluation of Health Related Quality of Life (HRQL) and has performed research on the operating properties of HRQL instruments.